Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Kshitija Iyer
A characteristic feature of the beginning of the XXI century medicine is that the achievement of bio-medical, diagnostic disciplines significantly outperforms progress to the clinic for the treatment of the most common diseases in the population. It atherosclerosis, diabetes, essential hypertension, and obesity, figuratively these diseases we call "metabolic pandemic". The frequency of these diseases in the populations of developed countries continues to increase, and all the efforts of clinicians and pharmaceutical companies do not produce the desired result, with the etiological factors are beginning to be better understood, which, however, cannot be said with regard to the pathogenesis. If the high expectations for the clinical use of genetics and genomics, gene polymorphisms have not justified, the possibility of metabolomics and proteomics are so great that their use in the diagnosis has not yet begun. We are not prepared to give the diagnostic interpretation of biochemical data in order to offer us the modern methods of physical chemistry, which at the same time, the concentration of dozens of proteins, substrates and metabolites. We cannot use the results of modern methods of diagnosis; we have no theoretical base - the modern theory of disease. It formed a large distance (gap) between the possibilities of the use of modern methods of research and its real application in the diagnosis of metabolic pandemics.